Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with
low and intermediate risk of myelodysplastic syndrome (MDS).